An accumulating body of evidence suggests that in the era of immunotherapy, high tumor mutational burden (TMB), DNA damage-response mutations, the presence of genomic instability, and high PD-L1 expression make bladder cancer suitable for immunotherapy [19]. The gene discussed is CD274; the disease is neoplasm.